UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported)

November 6, 2008

 

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-50884

94-3120386

(Commission File Number)

(IRS Employer Identification No.)

 

4320 Forest Park Avenue, Suite 100, St. Louis, Missouri

63108

(Address of Principal Executive Offices)

(Zip Code)

 

 

(314) 678-6100

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 


Item 2.02.

Results of Operations and Financial Condition

 

On November 6, 2008, Stereotaxis, Inc. issued a press release (the “Earnings Release”) setting forth its financial results for the third quarter of fiscal 2008. A copy of the Earnings Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.

 

Item 7.01.

Regulation FD Disclosure.

 

On November 6, 2008, Stereotaxis, Inc. issued a press release (the “Press Release”) announcing certain changes in management effective January 1, 2009. A copy of the Press Release is being filed as Exhibit 99.2 hereto, and the statements contained therein are incorporated by reference herein.

 

In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02, Item 7.01 and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

99.1

Stereotaxis, Inc. Earnings Release dated November 6, 2008.

 

99.2

Stereotaxis, Inc. Press Release dated November 6, 2008.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

STEREOTAXIS, INC.

 

 

 

Date: November 6, 2008

By:

/s/ James M. Stolze

 

Name:

James M. Stolze

 

Title:

Vice President and Chief Financial Officer

 

 


EXHIBIT INDEX

 

Exhibit No.

Document

 

99.1

Stereotaxis, Inc. Earnings Release dated November 6, 2008.

 

99.2

Stereotaxis, Inc. Press Release dated November 6, 2008.

 

 

 

Exhibit 99.1

 

 


Company Contact:

Jim Stolze

Chief Financial Officer

314-678-6105

 

Investor Contact:

EVC Group, Inc.

Douglas Sherk & Jenifer Kirtland

415-896-6820

 

Media Contact:

EVC Group, Inc.

Steve DiMattia

646-201-5445

 

Stereotaxis Reports Third Quarter 2008 Financial Results

Backlog Reaches $75 Million

$20 Million Existing Commitment from Two Shareholders Extended into 2010 Significantly Expands Operating Flexibility

Evaluation of Magnetic Irrigated Catheter in Europe Results in Excellent Outcomes

 

St. Louis, MO, November 6, 2008 —Stereotaxis, Inc. (NASDAQ: STXS) today reported its financial results for the third quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $10.6 million as the Company recognized revenue on six Niobe® Magnetic Navigation Systems and shipped three additional systems for which it expects to recognize revenue in the fourth quarter of 2008 and first quarter of 2009. Revenue from Niobe® and Odyssey™ systems totaled $7.4 million, while disposables, services and accessories revenue was $3.2 million. Revenue in the third quarter of 2007 was $12.0 million. Operating expenses in the recent third quarter declined by $2.6 million, or 14% from the third quarter of last year, and $1.5 million, or eight percent compared to the second quarter of 2008, excluding the costs related to the re-engineering of the magnetic irrigated catheter in the second quarter.

 

“While the hospital capital equipment market has been impacted by the credit crisis, electrophysiology (EP) lab spending on projects, programs and systems that help build overall hospital revenue remains relatively robust and we are capitalizing on the value that Stereotaxis brings to the marketplace,” said Bevil Hogg, Chief Executive Officer. “During the quarter, we set an all time high for recurring revenue, set a new record for backlog and generated $13 million in new orders. We are also poised to accelerate our momentum in the market as our partner Biosense Webster has completed the patient enrollment for the external evaluation of our partnered magnetic irrigated catheter. The catheter has been evaluated at nine sites, primarily in Europe, and a combined 92 cases were performed. The results are exemplary. The catheter met or exceeded all of the end points of the evaluation, including the long-standing exceptional level of safety associated with catheters used with Niobe systems. Approximately 75% of these procedures were to treat atrial fibrillation, and half of these were on patients with persistent atrial fibrillation, a more difficult form of the disease. In addition, the utilization rate of the Niobe system at the nine centers that participated in the evaluation increased significantly as compared to the utilization rate prior to the evaluation period, confirming our expectations that we should see a broad increase in the usage of our systems with the availability of the magnetic irrigated catheter. We continue to anticipate that the U.S. regulatory approval and subsequent launch of the magnetic irrigated catheter will take place shortly after its debut in the European market,” added Mr. Hogg.

 


 

“We continued to make good progress on a number of other important initiatives during the third quarter,” said Michael Kaminski, President and Chief Operating Officer of Stereotaxis. “While U.S. orders of our Niobe system were challenged by the lack of the irrigated catheter and reference site development, European order growth has been especially strong throughout the year. We believe our European order growth is being fueled by the very favorable first clinician use of the irrigated catheter in 2007 and customer access to reference sites. Recurring revenue from disposables and services represented 30% of total revenue in the recent third quarter compared with 21% in the same period of 2007 and exceeded $3 million for the first time in any quarterly reporting period in the Company’s history. We booked approximately $13 million in new orders and backlog reached a record $75 million. Very importantly, we continue to drive reductions in our operating expenses, resulting in improved leverage and enhanced bottom-line potential.”

 

“We are also seeing increased demand for Odyssey and Odyssey Cinema™,” continued Mr. Kaminski. “Early last month we announced the commercialization of Cinema. This innovative new product records procedures and enables physicians to receive a real-time high definition view from any point in the network of installed Odyssey systems. It will be a significant new tool for clinical collaboration, remote consultation and training. We are seeing growing interest in Odyssey across a broad range of interventional labs and have generated a total of 34 Odyssey orders in 2008.”

 

“We ended the quarter with $19.8 million in cash and cash equivalents. Recently, we reached an agreement with two Stereotaxis shareholders to extend the term of a $20 million commitment that they provided the Company this February through early 2010. We believe that this flexibility, along with other resources, including funds received through our arrangement with Biosense Webster as well as our bank line, provide us with a firm foundation for growth through 2009,” Mr. Kaminski concluded.

 

“With the launch of the irrigated catheter in Europe, and expected launch in the U.S. in the short term, growing utilization, growing recurring revenue, expanding margins and a broad platform, Stereotaxis has in place the building blocks to drive consistent growth, achieve profitability, and generate increased shareholder returns,” said Mr. Hogg. “We have reached a point where my expertise in creating technologies and companies surrounding those technologies should be succeeded by someone with the expertise and focus on all levels of operational execution. With that thought in mind, I take great pleasure in reporting today that I’ve been working with the Board on a transition plan that involves me passing the CEO baton to Mike, effective January 1, 2009. The Board and I believe that Mike has demonstrated the operational capability as well as the strategic vision to drive this company forward and achieve improved operating results. I will play an active role in the Company at the Board level and look forward to working closely with Mike as we move into 2009,” Mr. Hogg concluded.

 

Third Quarter and Nine Month Financial Performance

 

Gross margin for the quarter was $6.9 million, or 66% of revenue, compared with $8.0 million, or 67% of revenue in the third quarter of 2007.

 

Third quarter operating expenses decreased 14% to $16.1 million, compared to $18.7 million in the third quarter of 2007.

 

R&D expenses for the quarter ended September 30, 2008 were $4.4 million, compared with $6.7 million in the third quarter of 2007.

 


The Company reported a net loss for the third quarter of 2008 of $10.1 million, or $(0.28) per share. This compares to a net loss of $10.4 million, or $(0.29) per share, in the third quarter of 2007. The weighted average shares for the recent third quarter were 36.6 million compared with 36.3 million in the third quarter of last year.

 

For the first nine months of 2008, revenue totaled $28.2 million compared with revenue of $29.0 million for the first nine months of 2007. The Company reported a net loss of $36.4 million through the recent nine month period versus a net loss of $35.9 million for the first nine months of 2007. On a per share basis, the first nine months net loss in 2008 was $(1.00) compared with $(1.01) in the comparable period of 2007.

 

Cash used in operations was $5.5 million for the third quarter of 2008, and cash and investments at September 30, 2008 totaled $19.8 million, compared to $23.7 million at December 31, 2007.

 

Conference Call Information

The Company has scheduled a conference call for 8:30 a.m. Eastern Standard Time today to discuss its financial results for the third quarter. To access the conference call, please dial (800) 240-2134. International participants can call (303) 275-2170. An audio replay of the call will be available for seven days following the call at (800) 405-2236 for U.S. callers or (303) 590-3000 for those calling outside the U.S. The password required to access the replay is 11120546#. The call will also be available on the Internet live and for 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=52099

 

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

 


STEREOTAXIS, INC.

STATEMENTS OF OPERATIONS

(Unaudited)

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2008

 

2007

 

2008

 

2007

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

System

$

7,365,480 

 

$

9,500,848 

 

$

19,641,188 

 

$

22,479,877 

Disposables, service and accessories

 

3,186,169 

 

 

2,546,906 

 

 

8,597,503 

 

 

6,564,071 

Total revenue

 

10,551,649 

 

 

12,047,754 

 

 

28,238,691 

 

 

29,043,948 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

 

 

 

 

 

 

 

 

 

System

 

3,098,477 

 

 

3,541,756 

 

 

8,822,745 

 

 

8,024,046 

Disposables, service and accessories

 

543,071 

 

 

491,827 

 

 

1,427,501 

 

 

1,732,562 

Inventory impairment

 

– 

 

 

– 

 

 

– 

 

 

1,870,653 

Total cost of revenue

 

3,641,548 

 

 

4,033,583 

 

 

10,250,246 

 

 

11,627,261 

 

 

 

 

 

 

 

 

 

 

 

 

Gross margin

 

6,910,101 

 

 

8,014,171 

 

 

17,988,445 

 

 

17,416,687 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

4,380,466 

 

 

6,690,032 

 

 

13,861,339 

 

 

19,475,675 

Sales and marketing

 

7,012,264 

 

 

7,667,013 

 

 

23,297,003 

 

 

20,733,407 

General and administration

 

4,719,779 

 

 

4,320,208 

 

 

15,458,115 

 

 

14,112,033 

Total operating expenses

 

16,112,509 

 

 

18,677,253 

 

 

52,616,457 

 

 

54,321,115 

Operating loss

 

(9,202,408)

 

 

(10,663,082)

 

 

(34,628,012)

 

 

(36,904,428)

Interest income

 

33,711 

 

 

339,087

 

 

165,665 

 

 

1,212,644 

Interest expense

 

(904,428)

 

 

(74,267)

 

 

(1,931,606)

 

 

(216,499)

Net loss

$

(10,073,125)

 

$

(10,398,262)

 

$

(36,393,953)

 

$

(35,908,283)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

$

(0.28)

 

$

(0.29)

 

$

(1.00)

 

$

(1.01)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in computing net loss per common share:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

36,612,877 

 

 

36,256,089 

 

 

36,541,593 

 

 

35,612,871 

 


 

STEREOTAXIS, INC.

BALANCE SHEETS

 

 

September 30,
2008

 

December 31,
2007

 

 

(Unaudited)

 

 

 

Assets

 

 

 

 

 

Current Assets:

 

 

 

 

 

Cash and cash equivalents

$

19,784,987 

 

$

17,022,200 

Short-term investments

 

– 

 

 

6,634,178 

Accounts receivable, net of allowance of $303,854 and $189,040 in 2008
and 2007, respectively

 

13,117,362 

 

 

13,757,270 

Current portion of long-term receivables

 

198,351 

 

 

136,430 

Inventories

 

8,359,590 

 

 

9,964,460 

Prepaid expenses and other current assets

 

5,007,969 

 

 

3,421,202 

Total current assets

 

46,468,259 

 

 

50,935,740 

Property and equipment, net

 

5,857,675 

 

 

7,011,763 

Intangible assets

 

1,311,111 

 

 

1,411,111 

Long-term Receivables

 

306,030 

 

 

272,859 

Long-term Investments

 

469,842 

 

 

– 

Other assets

 

662,672 

 

 

844,321 

Total assets

$

55,075,589 

 

$

60,475,794 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders' equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Current maturities of long-term debt

$

17,957,046 

 

$

972,222 

Accounts payable

 

4,512,604 

 

 

7,349,426 

Accrued liabilities

 

7,556,442 

 

 

11,913,418 

Deferred contract revenue

 

13,572,095 

 

 

8,774,958 

Total current liabilities

 

43,598,187 

 

 

29,010,024 

 

 

 

 

 

 

Long term debt, less current maturities

 

15,469,858 

 

 

6,000,000 

Long term deferred contract revenue

 

1,099,341 

 

 

942,573 

Other liabilities

 

166,874 

 

 

328,790 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

Preferred stock, par value $0.001; 10,000,000 shares authorized at 2008
and 2007; none outstanding at 2008 and 2007

 

– 

 

 

– 

Common stock, par value $0.001; 100,000,000 shares authorized at 2008
and 2007; 37,428,311 and 37,132,529 issued at 2008 and 2007, respectively

 

37,428 

 

 

37,133 

Additional paid-in capital

 

283,376,206 

 

 

276,433,662 

Treasury stock, 40,151 shares at 2008 and 2007

 

(205,999)

 

 

(205,999)

Accumulated deficit

 

(288,466,306)

 

 

(252,072,353)

Accumulated other comprehensive gain

 

– 

 

 

1,964 

Total stockholders' equity (deficit)

 

(5,258,671)

 

 

24,194,407 

Total liabilities and stockholders' equity (deficit)

$

55,075,589 

 

$

60,475,794 

 

 

 

Exhibit 99.2

 


Company Contact:

Jim Stolze

Chief Financial Officer

314-678-6105

 

Investor Contact:

EVC Group, Inc.

Doug Sherk & Jenifer Kirtland

415-896-6820

 

Media Contact:

EVC Group, Inc.

Steve DiMattia

646-201-5445

 

Stereotaxis Announces New Management Appointment

 

Michael P. Kaminski Named Chief Executive Officer, Effective

January 1, 2009

 

St. Louis, MO November 6, 2008—Stereotaxis, Inc. (Nasdaq: STXS), today announced a leadership transition plan under which Michael P. Kaminski, currently President and Chief Operating Officer and a member of the Board, will assume the title and responsibilities of Chief Executive Officer, effective January 1, 2009. At that time, he will replace Bevil J. Hogg, who has served as the CEO since 1997 and will remain an active member of the Company’s Board of Directors.

 

“With the expected return of the magnetic irrigated catheter in the short term, Stereotaxis is poised to drive towards fully implementing its business plan with a strong focus on commercial success,” said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. “We have reached a point where my own expertise in creating a new technology and the organization to support it should ideally be succeeded by a leader who brings the experience, expertise and focus necessary for operational execution and who can lead Stereotaxis to greater commercial success. Therefore, I’ve been working with the Board on a transition plan that involves my passing the CEO baton to Mike as of January 1, 2009. The Board and I believe that Mike has demonstrated the operational capability as well as the strategic vision to drive this company forward and achieve increasing levels of shareholder returns.”

 

Mr. Kaminski, 48, joined Stereotaxis in April 2002 as Chief Operating Officer. Prior to coming to Stereotaxis, he spent nearly 20 years with Hill-Rom Company (Hillenbrand Industries). In his last position as Senior Vice President of North American Sales and Service, he was responsible for sales and service for the North American hospital

 


business with revenue exceeding $750 million. Mr. Kaminski began his career at Hill-Rom in a manufacturing management position and then worked in several functional departments, including sales, marketing, purchasing, new product development, and general management of multiple businesses. Over this 20 year period, Hill-Rom grew from $80 million to over $1.2 billion in worldwide revenues. Mr. Kaminski has a B.S. in Marketing from Indiana University and an M.B.A. from Xavier University.

 

“I am honored to succeed Bevil as the CEO and recognize his substantial contributions to building Stereotaxis,” said Michael Kaminski, President and Chief Operating Officer of Stereotaxis. “I look forward to leading our talented, highly skilled team of professionals. We continue to work hard on achieving our goal of making the Niobe® Magnetic Navigation System the standard of care for the treatment of cardiac arrhythmias and complex coronary disease worldwide. Today our Company offers a broad and innovative product line, with a reputation for safety and efficacy unsurpassed in the industry. We have recently established a business model that will allow us to achieve profitability, based on expanding our system placements, building recurring revenues, and adopting strict cost controls. With the imminent commercialization of the magnetic irrigated catheter, and our recently enhanced product line, we believe we are well positioned to achieve renewed growth and commercial success in the cardiology marketplace.”

 

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

 

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to

 


contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

 

###

 

 

Innovation Day